Editas Medicine
Develops an in vivo CRISPR candidate for lowering LDL cholesterol.
$3.14
After-hours close−0.01 (−0.30%)
At close$3.15(−4.55%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 78.31%120.18M sharesInsiders 0.29%437.7K sharesOther 21.40%32.85M shares
Shares outstanding 153.46M · Float 141.95M · 92.5% free float
Institutions13F, as of Jun 30, 2026
224 holders · 120.18M shares · 37 new positions · 113 increased · 41 reduced · 29 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 11.11M | 7.24% | +11.11Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 10.59M | 6.90% | +1.33M | Aug 7, 2026 |
| Ra Capital Management, L.P. | 8.89M | 5.79% | +8.89Mnew | Aug 14, 2026 |
| Adar1 Capital Management, LLC | 8.89M | 5.79% | +8.89Mnew | Aug 14, 2026 |
| Commodore Capital LP | 8.89M | 5.79% | +8.89Mnew | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.14M | 4.00% | +1.94M | Aug 13, 2026 |
| Paradigm Biocapital Advisors LP | 5.59M | 3.64% | +5.59Mnew | Aug 14, 2026 |
| Opaleye Management Inc. | 3.86M | 2.52% | +1.93M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 9.90% | 16.05M | 13G | Jun 2, 2026 ↗ |
| BlackRock, Inc. | 7.90% | 6.54M | 13G | Apr 17, 2025 ↗ |
| ADAR1 Capital Management, LLC | 5.80% | 8.89M | 13G | Aug 14, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Gilmore Neil O'Neill | director, officer: CEO | 248.3K | 0.16% | Jun 5, 2026 |
| Erick Lucera | officer: EVP, CHIEF FINANCIAL OFFICER | 112.7K | 0.07% | Mar 5, 2025 |
| Linda Burkly | officer: EVP, CHIEF SCIENTIFIC OFFICER | 62.4K | 0.04% | Jul 29, 2026 |
| Amy Parison | officer: SVP, Chief Financial Officer | 14.3K | 0.01% | Aug 5, 2026 |
10 ten-percent owners hold 13.16M shares by Form 4, outside the officers-and-directors figure above · 17 people have not refiled in the last 18 months (4.80M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 678 | $2.58 | 14,292 |
| Jul 28, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 4,928 | $2.67 | 62,369 |
| Jun 3, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 731 | $2.70 | 67,297 |
| Jun 3, 2026 | Gilmore Neil O'Neilldirector, officer: CEO | Sale | 15,380 | $2.70 | 248,313 |
| Jun 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 464 | $2.70 | 14,970 |
| Mar 3, 2026 | Linda Burklyofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sale | 749 | $2.02 | 68,028 |
| Mar 3, 2026 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 474 | $2.02 | 15,434 |
| Mar 3, 2026 | Gilmore Neil O'Neilldirector, officer: CEO | Sale | 5,394 | $2.02 | 263,693 |
| Dec 3, 2025 | Amy Parisonofficer: SVP, Chief Financial Officer | Sale | 461 | $2.15 | 15,908 |
| Dec 3, 2025 | Gilmore Neil O'Neilldirector, officer: CEO | Sale | 5,603 | $2.15 | 269,087 |
CongressHouse and Senate disclosures
Not reported.